Streetbeat News

Analyst Ratings

NWG

Exane BNP Paribas analyst Guy Stebbings downgrades NatWest Group (NYSE:NWG) from Neutral to Underperform.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 12:01 pm

CLNN

CMG

COHR

FDX

LEGH

LITE

NKE

SKIN

SNOW

TSLA

UBER

Analysts have updated their price targets for several stocks, including Lumentum, FedEx, Clene, Chipotle, Snowflake, Tesla, Coherent, Nike, Beauty Health, Uber, and Legacy Housing. The changes include both upgrades and downgrades, with some stocks experiencing pre-market price movements.

Portfolio Pulse from Lisa Levin

June 21, 2023 | 12:00 pm

BTCUSD

Bitcoin (CRYPTO: BTC) is trading around $29,000, driven by increased investor optimism following crypto initiatives by financial institutions. Crypto Analyst 'Tony The Bull' suggests the Wyckoff Method may have predicted this trend, with large institutions like BlackRock and Charles Schwab acting as the 'Composite Man'.

Portfolio Pulse from Mehab Qureshi

June 21, 2023 | 11:45 am

TDW

BTIG analyst Gregory Lewis has initiated coverage on Tidewater (NYSE:TDW) with a Buy rating and a price target of $75.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 11:32 am

LEGH

EF Hutton analyst Tim Moore maintains a Buy rating on Legacy Housing (NASDAQ:LEGH) and raises the price target from $28 to $30.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 11:31 am

UBER

Oppenheimer analyst Jason Helfstein maintains an Outperform rating on Uber Technologies (NYSE:UBER) and raises the price target from $55 to $65.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 11:29 am

SLP

Oppenheimer analyst Francois Brisebois maintains an Outperform rating on Simulations Plus (NASDAQ:SLP) and raises the price target from $65 to $67.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 11:28 am

AQST

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates a Buy rating on Aquestive Therapeutics (NASDAQ:AQST) and maintains a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 11:27 am

FENC

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Fennec Pharmaceuticals (NASDAQ:FENC) and maintained an $18 price target.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 11:26 am

SGH

Rosenblatt analyst Kevin Cassidy reiterates a Buy rating on SMART Global Holdings (NASDAQ:SGH) and maintains a $35 price target.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 11:25 am